A Banner Year for New Drugs

12/26/12

[Editor’s note: To tap the wisdom of our distinguished group of Xconomists, we asked a few of them to answer this question heading into 2013: “What does your gut tell you will happen this year even though you don’t have data to prove it?”]

I think there will be even more FDA approvals for New Molecular Entities in 2013 compared with 2012 and 2011, which have been “banner years” for approvals. Why? Industry has stepped up their game on innovative medicines and the FDA has now set a better balance of risk and benefit.

 

John Maraganore is the CEO of Alnylam Pharmaceuticals. Follow @

By posting a comment, you agree to our terms and conditions.

  • avid reader

    useless@useless .com